Bard
This article was originally published in The Gray Sheet
Executive Summary
Murray Hill, N.J. firm purchases assets of Source Tech, its supplier of iodine radioactive isotope seeds for use in brachytherapy in treating prostate cancer. "Vertically integrating the manufacture of iodine seeds is a significant step, giving us greater flexibility and control of our business," according to Bard CEO William Longfield. The company also markets palladium seeds for the same indication...